|
gptkbp:instanceOf
|
gptkb:gene_therapy
gptkb:immunotherapy
gptkb:genetically_engineered_cell
|
|
gptkbp:administeredBy
|
gptkb:hospital
infusion
specialized treatment center
|
|
gptkbp:alternativeName
|
chimeric antigen receptor T cell
|
|
gptkbp:approvedBy
|
gptkb:FDA
2017
|
|
gptkbp:approvedProduct
|
gptkb:Carvykti
gptkb:Abecma
gptkb:Tecartus
gptkb:Kymriah
gptkb:Yescarta
gptkb:Breyanzi
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Phase_I
Phase II
Phase III
|
|
gptkbp:developedBy
|
genetic engineering
|
|
gptkbp:hasComponent
|
gptkb:cell_surface_receptor
chimeric antigen receptor
|
|
gptkbp:manufacturer
|
patient's own T cells
|
|
gptkbp:mechanismOfAction
|
T cell activation
antigen recognition
tumor cell lysis
|
|
gptkbp:requires
|
genetic modification
quality control
cell expansion
leukapheresis
lymphodepleting chemotherapy
cryopreservation
|
|
gptkbp:riskFactor
|
infection
hypogammaglobulinemia
B cell aplasia
|
|
gptkbp:sideEffect
|
neurotoxicity
cytokine release syndrome
|
|
gptkbp:studiedBy
|
gptkb:Carl_June
gptkb:Michel_Sadelain
autoimmune diseases
solid tumors
James N. Kochenderfer
|
|
gptkbp:target
|
gptkb:CD19
gptkb:BCMA
|
|
gptkbp:treatment
|
gptkb:mantle_cell_lymphoma
gptkb:leukemia
multiple myeloma
diffuse large B-cell lymphoma
follicular lymphoma
|
|
gptkbp:usedFor
|
gptkb:cancer
hematologic malignancies
|
|
gptkbp:bfsParent
|
gptkb:CIK_cell
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CAR-T cell
|